Login
NeuroTrials.ai The Neurology Trials Database
About Contact
Trials Latest Wiki Journal Evidence
All Stroke Headache Epilepsy Immunology Movement Neuromuscular Dementia Oncology
AI-Powered Neurology Evidence Search
Open Full Site →

Headache Trials

June 2026 · 14 Trials · NeuroTrials.ai
FEATURED ARTICLE
Does a single intravenous infusion of Lu AG09222, an anti-PACAP monoclonal antibody, reduce migraine days in patients with prior preventive treatment failures?

HOPE

A Monoclonal Antibody to PACAP for Migraine Prevention

New England Journal of Medicine · 2024

Bottom Line: In this phase 2 proof-of-concept trial, a single 750-mg IV infusion of the anti-PACAP monoclonal antibody Lu AG09222 reduced monthly migraine days by 2.0 days more than placebo over the subsequent 4 weeks, supporting PACAP inhibition as a viable mechanism for migraine prevention and warranting larger phase 3 trials.

MIGRAINE 5

Can a CGRP antibody actually prevent migraines in children and teens?

SPACE - Fremanezumab Pediatric

2026
View Details →

Is vaporized cannabis effective for the acute treatment of migraine attacks?

Cannabis for Acute Migraine

2026
Headache: The Journal of Head and Face Pain

Does early initiation of erenumab in patients with episodic migraine who failed 1 or 2 previous preventive treatments provide improved long-term efficacy, tolerability, adherence, and patient satisfaction compared with nonspecific oral migraine preventive medication?

APPRAISE

2024
JAMA Neurology

Is CGRP inhibitor use associated with an increased risk of cardiovascular events in patients with migraine?

CGRP-CV

2026
Neurology

Is vaporized cannabis (THC-dominant, CBD-dominant, or THC+CBD) superior to placebo for the acute treatment of migraine attacks?

CANNABIS MIGRAINE

2024
medRxiv (preprint)

MIGRAINE 1

Does eptinezumab combined with brief patient education reduce migraine burden more than patient education alone in adults with chronic migraine and medication-overuse headache?

RESOLUTION

2026
Neurology

CHRONIC MIGRAINE 3

Is atogepant effective for preventive treatment of chronic migraine in patients with and without acute medication overuse?

PROGRESS

2024
Neurology

Does adding a 28-day prednisone taper to galcanezumab improve outcomes in medication overuse headache compared with either treatment alone?

Steroids + Galcanezumab for MOH

2025
Revue Neurologique

Which treatment strategy—withdrawal, prevention (oral, anti-CGRP, botulinum toxin), education, neurostimulation, or combinations—is most effective at reducing monthly headache days in patients with medication-overuse headache?

MOH NMA Liu 2025

2025
The Journal of Headache and Pain

MIGRAINE PROPHYLAXIS 2

Does fremanezumab reduce monthly migraine days and depressive symptoms in patients with migraine and comorbid DSM-5 major depressive disorder?

UNITE

2025
JAMA Neurology

Is amitriptyline an effective migraine prophylactic, and is the benefit independent of its antidepressant action?

Amitriptyline Couch

1976
Neurology

CLUSTER HEADACHE (CGRP) 1

Is eptinezumab 400 mg IV every 12 weeks safe, tolerable, and effective for long-term prevention of chronic cluster headache?

CHRONICLE

2025
Lancet Neurology

CLUSTER HEADACHE 2

Do anti-CGRP monoclonal antibodies effectively prevent attacks in episodic and chronic cluster headache?

KOLAKOWSKI ET AL 2026 EFFICACY

2026
Cephalalgia

Can a CGRP antibody prevent episodic cluster headache attacks?

GALiC

2019
View Details →